• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    8/25/23 5:31:51 PM ET
    $ADAP
    $AEON
    $APM
    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • MSP Recovery (NASDAQ:LIFW) stock increased by 14.0% to $0.08 during Friday's after-market session. At the close, MSP Recovery's trading volume reached 118.4K shares. This is 18.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $25.1 million.
    • SCWorx (NASDAQ:WORX) stock increased by 8.35% to $0.23. The company's market cap stands at $3.7 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 7.02% to $0.83. The company's market cap stands at $188.8 million.
    • Inhibikase Therapeutics (NASDAQ:IKT) stock increased by 6.66% to $2.24. The market value of their outstanding shares is at $11.9 million.
    • Axcella Health (NASDAQ:AXLA) stock rose 6.36% to $0.12. Axcella Health's trading volume hit 149.2K shares by close, accounting for 12.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $8.6 million.
    • SenesTech (NASDAQ:SNES) stock rose 6.23% to $0.68. The company's market cap stands at $2.0 million.

    Losers

    • Scilex Holding (NASDAQ:SCLX) stock declined by 10.9% to $2.93 during Friday's after-market session. Trading volume for this security closed at 51.0K, accounting for 9.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $436.7 million.
    • AEON Biopharma (AMEX:AEON) stock decreased by 8.9% to $4.2. The company's market cap stands at $156.0 million.
    • Infinity Pharmaceuticals (NASDAQ:INFI) shares declined by 7.62% to $0.08. This security traded at a volume of 54.9K shares come close, making up 1.7% of its average volume over the last 100 days. The company's market cap stands at $7.3 million.
    • Clene (NASDAQ:CLNN) stock declined by 6.66% to $0.67. The company's market cap stands at $85.9 million.
    • Aptorum Gr (NASDAQ:APM) stock decreased by 6.37% to $2.06. At the close, Aptorum Gr's trading volume reached 72.8K shares. This is 604.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $8.5 million.
    • Catalyst Biosciences (NASDAQ:CBIO) shares fell 5.36% to $0.55. Trading volume for this security closed at 83.6K, accounting for 12.6% of its average full-day volume over the last 100 days. The company's market cap stands at $20.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $AEON
    $APM
    $AXLA

    CompanyDatePrice TargetRatingAnalyst
    Inhibikase Therapeutics Inc.
    $IKT
    3/4/2026$4.00Buy
    Ladenburg Thalmann
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Inhibikase Therapeutics Inc.
    $IKT
    1/21/2026$6.00Buy
    BofA Securities
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Inhibikase Therapeutics Inc.
    $IKT
    12/26/2025$8.00Buy
    H.C. Wainwright
    Inhibikase Therapeutics Inc.
    $IKT
    12/11/2025$4.00Overweight
    Cantor Fitzgerald
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADAP
    $AEON
    $APM
    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

    – Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (

    3/30/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 35,325 shares of the Company's ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 26, 2026 and were material to each employee's accept

    3/27/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

    WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the year ended December 31, 2025 and highlighted recent developments. "The fourth quarter of 2025 was a transformational quarter for the Company as we transitioned to a global pivotal Phase 3 clinical study in Pulmonary Arterial Hypertension following receipt of a Written Response from a Type C interaction from the United States Food and Drug Administration," said Mark I

    3/26/26 4:01:00 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AEON
    $APM
    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ugwumba Chidozie

    4 - Clene Inc. (0001822791) (Issuer)

    3/26/26 5:39:47 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    CHIEF MEDICAL OFFICER Oh Chad was granted 2,179,372 shares, increasing direct ownership by 53,626% to 2,183,436 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/11/26 8:13:33 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AEON
    $APM
    $AXLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADAP
    $AEON
    $APM
    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Inhibikase Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $4.00

    3/4/26 8:37:45 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Inhibikase Therapeutics with a new price target

    BofA Securities initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $6.00

    1/21/26 8:55:17 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AEON
    $APM
    $AXLA
    SEC Filings

    View All

    Amendment: SEC Form S-4/A filed by Aptorum Group Limited

    S-4/A - Aptorum Group Ltd (0001734005) (Filer)

    3/30/26 5:59:13 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by AEON Biopharma Inc.

    10-K - AEON Biopharma, Inc. (0001837607) (Filer)

    3/30/26 5:36:07 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AEON Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AEON Biopharma, Inc. (0001837607) (Filer)

    3/30/26 5:29:32 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AEON
    $APM
    $AXLA
    Leadership Updates

    Live Leadership Updates

    View All

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AEON
    $APM
    $AXLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ADAP
    $AEON
    $APM
    $AXLA
    Financials

    Live finance-specific insights

    View All

    AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

    – Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (

    3/30/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials